Comparisons of changes in circulating vascular endothelial growth factor-A and renal vascular parameters after intravitreal ranibizumab or aflibercept for retinal vascular disease
Not Applicable
- Conditions
- age-related macular degeneration, diabetic macular edema, macular edema secondary to retinal vein occlusion
- Registration Number
- JPRN-UMIN000036143
- Lead Sponsor
- Tosei General Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients who had received systemic anti-VEGF therapy for malignancy. 2)Patients who were currently on dialysis. 3)Patients who had undergone vitrectomy in the treated eye. 4)Patients who had severely high albuminuria (A3 category, KDIGO 2012).
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method rine albumin to creatinine ratio 3 months after treatment
- Secondary Outcome Measures
Name Time Method 1)Circulating total VEGF-A and VEGF-A165b levels 3 months after treatment 2)Blood pressure 3 months after treatment 3)Ankle brachial index 3 months after treatment